South Korean biotech startup Galux has raised $29 million in Series B funding, taking its total funding to $47 million. The company will use the investment to strengthen its AI-based protein and antibody design platform, expand research capabilities, and speed up preclinical drug discovery, while growing partnerships with pharma companies in Korea and globally.